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The impaired capacity of skeletal muscle to switch
between the oxidation of fatty acid (FA) and glucose is
linked to disordered metabolic homeostasis. To under-
stand howmuscle FA oxidation affects systemic glucose,
we studied mice with a skeletal muscle–specific defi-
ciency of long-chain acyl-CoA synthetase (ACSL)1.
ACSL1 deficiency caused a 91% loss of ACSL-specific
activity and a 60–85% decrease in muscle FA oxidation.
Acsl1M2/2 mice were more insulin sensitive, and, during
an overnight fast, their respiratory exchange ratio was
higher, indicating greater glucose use. During endurance
exercise, Acsl1M2/2 mice ran only 48% as far as controls.
At the time that Acsl1M2/2 mice were exhausted but con-
trol mice continued to run, liver and muscle glycogen and
triacylglycerol stores were similar in both genotypes;
however, plasma glucose concentrations in Acsl1M2/2
mice were ∼40 mg/dL, whereas glucose concentrations
in controls were ∼90 mg/dL. Excess use of glucose and
the likely use of amino acids for fuel within muscle de-
pleted glucose reserves and diminished substrate avail-
ability for hepatic gluconeogenesis. Surprisingly, the
content of muscle acyl-CoA at exhaustion was markedly
elevated, indicating that acyl-CoAs synthesized by other
ACSL isoforms were not available for b-oxidation. This
compartmentalization of acyl-CoAs resulted in both an
excessive glucose requirement and severely compro-
mised systemic glucose homeostasis.
Skeletal muscle switches between the use of glucose and
lipid, depending on fuel availability and energy require-
ments. Metabolic inflexibility, a state of impaired capacity
for fuel switching between fatty acids (FAs) and glucose
(1), is associated with metabolic disorders such as insulin
resistance, diabetes, and the cardiometabolic syndrome
(2–5), whereas enhanced oxidation of FA spares glucose
(6,7). Metabolic inflexibility occurs in human disorders in
which b-oxidation is genetically impaired; these disorders
are associated with hepatic steatosis, myopathy, cardio-
myopathy, and episodes of fasting-induced nonketotic hy-
poglycemia (8). However, it remains uncertain how fuel
selection is regulated in skeletal muscle and how fuel in-
flexibility specifically impairs exercise tolerance and leads
to metabolic dysfunction (7,9).
Before FAs are used for oxidation or for the synthesis
of cholesterol esters, phospholipids, or triacylglycerol
(TAG), they must be activated to form acyl-CoAs by one
of a family of five long-chain acyl-CoA synthetases
(ACSLs), each encoded by a separate gene (10). We have
proposed that each ACSL isoform determines whether
FAs are channeled toward pathways of oxidation or com-
plex lipid biosynthesis (11). Data from ACSL1 deficiencies
in adipose, liver, heart, or macrophages suggest that chan-
neling is tissue-specific, but that in highly oxidative tis-
sues, the ACSL1 isoform directs FAs toward b-oxidation
(11–14). Thus, mice deficient in brown adipose ACSL1
cannot metabolize FAs for heat production and fail to
maintain a normal body temperature when placed in
a cold environment (13). Likewise, hearts that lack
ACSL1 cannot oxidize FAs for contractile energy, have an
eightfold increased use of glucose, and develop mammalian
target of rapamycin complex 1–mediated hypertrophy (14).
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ACSL1 is located on the mitochondrial outer mem-
brane, but it is unclear why its absence would block FA
oxidation; acyl-CoAs are amphipathic molecules that are
both soluble in water and able to integrate into membrane
monolayers via their hydrophobic acyl chains. In addition,
acyl-CoA binding protein and some isoforms of FA bind-
ing protein can bind and carry acyl-CoAs. Thus, an acyl-
CoA should be able to enter any downstream pathway,
unless the entry into one specific pathway versus another
depend on the relative substrate affinities of the initiating
acyltransferases.
The role of any ACSL isoform in skeletal muscle remains
unknown (6,15). Given the importance of lipid metabo-
lism in skeletal muscle and the key position of ACSL in
initiating most lipid metabolic pathways, we hypothe-
sized that a deficiency of ACSL1 would block the use of
FAs for energy, thereby impairing fuel selection during
exercise. To learn whether ACSL1 deficiency in skeletal
muscle impairs exercise capacity or alters whole-body
fuel metabolism, we studied the metabolic adaptation
of skeletal muscle–specific Acsl1 knockout mice (Acsl1M2/2)
to physiological challenges. Unexpectedly, acyl-CoA content
rose markedly during exercise, revealing that acyl-CoAs
synthesized by non-ACSL1 isoforms were retained in
a pool that was inaccessible for mitochondrial oxidation.
RESEARCH DESIGN AND METHODS
Muscle-Specific Acsl1 Knockout Mice
Homozygous floxed mice (Acsl1loxP/loxP) (12) were mated
with mice expressing Cre recombinase controlled by the
muscle-specific human skeletal actin (HSA) promoter
(catalog #006149; The Jackson Laboratory) to achieve
muscle-specific deletion of Acsl1. HSA-Cre is expressed in
the early embryo (16), and mice were born with deficient
ACSL1. Acsl1M2/2 (Acsl1loxP/loxP-HSACre) were mated with
Acsl1loxP/loxP mice to obtain Acsl1M2/2 and littermate con-
trols (Acsl1loxP/loxP). Because most measurements were
qualitatively similar in male and female Acsl1M2/2 mice
compared with controls, we report measurements from
only one sex. Procedures were approved by the University
of North Carolina Institutional Animal Care and Use Com-
mittee. Mice were kept in a pathogen-free barrier facility
(12-h dark/light cycle) and fed standard chow (Prolab RMH
3000; LabDiet, Richmond, IN). Between 8 and 25 weeks of
age, some mice were fed a high-fat diet (45%; D12451) or
a matched low-fat (10%; D12450B) standard diet (Research
Diets). Oral glucose (2.5 g D-glucose/kg body wt) and in-
traperitoneal insulin tolerance tests (control diet 0.35
units/kg body wt; high-fat diet 0.50 units/kg body wt)
(12) and glycerol tolerance tests (2 mg/kg body wt) (17)
were performed.
Metabolic analysis was performed in PhenoMaster/
LabMaster chambers (TSE Systems, Chesterfield, MO).
After 24 h of acclimatization, measurements were acquired
every 27 min for VO2, VCO2, respiratory exchange ratio
(RER), food intake, and physical activity.
Endurance Exercise
Mice (16–26 weeks of age) were acclimatized to a motor-
ized, speed–controlled treadmill with an electric shock
stimulus (Exer-3/6; Columbus Instruments, Columbus,
OH) for 3 consecutive days, starting from 0 to 16 m/min
and from 0 to 10% grade. On the study day, mice were
fasted for 2 h after 10:00 A.M. (“rested” state) to prevent
potential carbohydrate-induced increases in insulin with
a subsequent decrease in adipose lipolysis (18). Speed
was increased from 8 m/min by 2 m/min every 15 min
until reaching 18 m/min. Mice were maintained at this
speed until they refused to run. Tail blood was taken for
measurement of glucose and lactate levels. For measurement
of plasma metabolites and tissue glycogen, trunk blood and
tissues were collected at exhaustion. Blood and tissues were
taken from additional control mice after they had run for
the same length of time as the exhausted Acsl1M2/2 mice.
Metabolites, Western Blot Analysis, and Histology
Mice were fasted for 4 h (basal state) or 17 h. Plasma
metabolites were measured colorimetrically (glucose, non-
esterified FA; Wako, Richmond, VA; triglyceride; Stanbio
Laboratory, Elkhart, IN) or enzymatically (b-hydroxybutyrate,
creatine kinase; Stanbio Laboratory), with a mouse insulin
ELISA kit (Millipore, Billerica, MA) or with a lactometer
(Lactate Plus; Nova Biomedical, Waltham, MA). Glycogen
was measured in snap-frozen tissues (19). TAG was mea-
sured in tissue lipid extracts (Stanbio Laboratory) (20,21).
Gastrocnemius muscle was fixed and stained (22).
Tissue proteins were blotted with primary antibodies
to detect ACSL1, Akt, and pAkt (Cell Signaling Technol-
ogy, Danvers, MA); ACSL4 (Santa Cruz Biotechnology, Santa
Cruz, CA); and GLUT1 and GAPDH (Abcam, Cambridge,
MA).
Insulin Signaling
Mice were injected with PBS or insulin (2 units/kg body
wt i.p.). Glucose was measured by glucometer to ensure
adequate lowering. Ten minutes later, tissue superna-
tants were prepared, electrophoresed, and blotted for
antiphospho-Akt (Thr-308) and total Akt (Cell Signal-
ing Technology) (20).
Quantitative PCR
Genomic/mitochondrial DNA and total RNA were
extracted from tissues (TRIzol; Invitrogen, Carlsbad, CA;
AllPrep DNA/RNA kit; Qiagen, Valencia, CA). cDNA was
synthesized (Applied Biosystems). Gene expression and
mitochondrial DNA content were determined with Abso-
lute QPCR Sybr Green Fluorescein Mix (Thermo Scientific,
West Palm Beach, FL). Expression of target genes
(Supplementary Table 1) was normalized to endogenous
b-actin, tubulin, or H19 and calculated using the 22DDCt
method (23).
ACSL Activity, FA Oxidation, and Metabolomics
ACSL-specific activity was measured in tissue homogenates
from 13- to 16-week-old mice (24). CO2 and acid soluble
metabolites (ASM) were measured from gastrocnemius
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homogenates incubated for 30 min in 100 mmol/L KCl, 40
mmol/L Tris-HCl, 10 mmol/L Tris base, 5 mmol/L
MgCl2$6H2O, 1 mmol/L EDTA, and 1 mmol/L ATP, pH
7.4, and [1-14C]palmitate or [1-14C]palmitoyl-CoA (25).
Amino acids, acyl-carnitines, acyl-CoAs, and ceramides
were analyzed by flow injection tandem mass spectrometry
(26,27). Organic acids were analyzed by gas chromatography–
mass spectrometry (27).
For whole-muscle incubations, soleus and extensor
digitorum longus muscles were removed (fed state) and
incubated (28) with gassing in Krebs-Henseleit buffer,
5 mmol/L D-glucose, 1 mmol/L L-carnitine, 12.5 mmol/L
HEPES, and 1% BSA. Media were changed after 30 min.
Contralateral muscles were incubated with 1 mmol/L
[1-14C]oleate (2 mCi/ml) or with 5 mmol/L [U-14C]glucose
(2 mCi/ml), 100 nmol/L insulin, and 0.75 mmol/L palmi-
tate for 90 min. Media were transferred to culture tubes





Data were analyzed using a two-tailed Student t test or
two-way ANOVA where appropriate (SAS, Inc.) and were
expressed as means 6 SE. Statistical significance was de-
fined as P , 0.05.
RESULTS
FA Oxidation Was Severely Diminished in Acsl1M2/2
Skeletal Muscle
In Acsl1M2/2 mice, weight and activity did not differ from
those in littermate controls, and female reproduction was
normal. ACSL1 protein was absent in Acsl1M2/2 gastroc-
nemius muscle but was present in the heart (Fig. 1A) and
liver (Supplementary Fig. 1A). Acsl1 mRNA expression in
gastrocnemius muscle was 86% lower than that in con-
trols, with no compensatory increases in other ACSL iso-
forms (Fig. 1B). Compared with controls, the mRNA
content of Acsl4 was 30% lower in Acsl1M2/2 gastrocne-
mius muscle and 35% higher in soleus muscle (Supplemen-
tary Fig. 1B), but ACSL4 gastrocnemius muscle protein
content was unchanged (Supplementary Fig. 1C). ACSL-
specific activity was unchanged in the heart but was di-
minished by .90% in Acsl1M2/2 gastrocnemius muscle
(Fig. 1C). Residual ACSL activity represents the combined
activities of all remaining ACSL isoforms. These data show
that ACSL1 contributes the majority of total ACSL activity
in skeletal muscle.
Deficiency of ACSL1 caused a mild myopathy with
occasional central nuclei and cells surrounded by macro-
phages (Fig. 1D and E), but plasma creatine kinase activity
was not statistically elevated (Table 1). Compared with
controls, the sum of complete oxidation of [1-14C]palmitate
to CO2 plus incomplete oxidation to ASM was 83% and 63%
lower, respectively, in Acsl1M2/2 gastrocnemius and soleus
muscles (Fig. 1F). Unimpaired oxidation of [14C]palmitoyl-
CoA to CO2 (Fig. 1G) and the presence of normal mito-
chondrial DNA content (Supplementary Fig. 1D) indicated
that ACSL1 deficiency did not block the downstream FA
oxidation pathway or diminish mitochondrial respiratory
function. The significant decrease in FA oxidation in
Acsl1M2/2 muscle suggests that the ACSL1 isoform is re-
quired to activate FAs before they can be converted to
acyl-carnitines, enter the mitochondrial matrix, and un-
dergo b-oxidation; in contrast, acyl-CoAs were oxidized.
Because the preparation of homogenates or isolated
mitochondria alters normal organelle relationships, we
performed additional studies in permeabilized muscle
fibers. FA oxidation in permeabilized fibers was only 1%
of the oxidation in homogenates (compare Fig. 1F and H),
and neither glucose nor FA oxidation or FA incorporation
into complex lipids was impaired (Fig. 1I and J), suggest-
ing that maximal FA transport, similar to that of glucose,
may require specific transporters or ACSL isoforms that
are activated by muscle contraction. Experiments using
homogenates or isolated mitochondria would eliminate
the transport step and permit ACSL1 to directly activate
FAs and allow them to be converted to acyl-carnitines for
mitochondrial entry. Alternatively, in static muscle, per-
haps only very small amounts of FA enter the mitochon-
dria for oxidation, and these small amounts of acyl-CoAs
are supplied by non–ACSL1 isoforms such as ACSL5, which
is also present on the outer mitochondrial membrane (10).
ACSL1 Deficiency in Muscle Impairs Fasting Glucose
Homeostasis
To examine how the limitation in skeletal muscle FA
oxidation affects whole-body energy metabolism, we
challenged Acsl1M2/2 mice with an overnight fast, a state
in which FAs released from adipose become the major fuel
source for most organs. Acsl1M2/2 mice became mildly
hypoglycemic (plasma glucose level: 82 6 6 mg/dL vs.
137 6 24 mg/dL in controls) (Fig. 2A). Compared with
controls, basal plasma FA concentrations were 64% higher
in Acsl1M2/2 mice and rose further after an overnight fast
(0.58 6 0.04 vs. 0.25 6 0.05 mmol/L, respectively) (Fig.
2B). After fasting, the plasma TAG level was 46% higher in
Acsl1M2/2mice (Fig. 2C), and the plasma b-hydroxybutyrate
level was 71% higher (Fig. 2D), consistent with increased
hepatic b-oxidation of FA. Compared with fasting con-
trols, fasting Acsl1M2/2 mice stored 53% more TAG in
the liver (Fig. 2E and F), suggesting that the inability of
Acsl1M2/2 muscle to metabolize FA caused adipose-derived
FAs to relocate to the liver for re-esterification and storage
(29,30).
Overnight fasting depleted liver glycogen stores in
both control and knockout mice (Fig. 2G). Although
mRNA abundance of glucose-6-phophatase and phospho-
enolpyruvate carboxykinase increased similarly in both
genotypes (Fig. 2H), which is consistent with appropriate
gluconeogenic upregulation, this upregulation was insuf-
ficient to counteract hypoglycemia in Acsl1M2/2 mice,
probably because of diminished substrate availability
since a glycerol tolerance test showed enhanced gluconeo-
genesis (Fig. 2I). The gastrocnemius muscle of Acsl1M2/2
mice contained more GLUT1 protein (Fig. 2J). Weight
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gain, body composition (Supplementary Fig. 2), and glu-
cose tolerance test results showed no genotype differ-
ences in mice fed control or high-fat diets (Fig. 2K), but
less insulin was secreted by Acsl1M2/2 mice (Fig. 2L).
Enhanced insulin sensitivity was confirmed by insulin
tolerance tests (Fig. 2M), high basal pAkt (T308) levels
in the liver, and increased pAkt levels in the liver and
gastrocnemius muscle after insulin injection (Fig. 2N).
Taken together, these data show that, during fasting,
the inability of Acsl1M2/2 skeletal muscle to switch from
Figure 1—ACSL1 deficiency decreased ACSL-specific activity and FA oxidation in skeletal muscle. A: ACSL1 protein in the gastrocnemius
muscle and heart in Acsl1M2/2 and control mice. B: mRNA expression of Acsl1 isoforms in gastrocnemius relative to tubulin (males; n = 8).
C: ACSL-specific activity in homogenates from the gastrocnemius muscle and heart (n = 4). Histology (320) of control (D) and Acsl1M2/2 (E)
gastrocnemius. Thin arrows, central nuclei; thick arrow, macrophage infiltration. FA oxidation in homogenates from gastrocnemius and
soleus muscle from [1-14C]palmitate (F ) or [14C]palmitoyl-CoA (G) (n = 3–4). Oxidation (H) or incorporation (I) in isolated soleus or extensor
digitorum longus with [14C]16:0, or with [14C]glucose (J) (n = 5). *P < 0.05, compared with control littermates. EDL, extensor digitorum
longus; Gastroc, gastrocnemius.
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glucose to FA use resulted in an overflow of FAs to plasma
and liver, thereby increasing liver TAG and plasma VLDL
levels, diminishing plasma glucose levels, and increasing
insulin sensitivity.
Metabolic Inflexibility During Fasting
The RER (VCO2/VO2) was consistent with impaired fuel
switching from glucose to FA oxidation in Acsl1M2/2 mus-
cle (Fig. 3A). The RER did not differ between genotypes
when mice were fed chow (60% carbohydrate), suggesting
that muscle FA oxidation may not be critical without ex-
ercise, but when food was removed, the responses of the
two genotypes diverged. Whether or not food is available
at the start of the dark cycle, the RER normally rises; this
rise in RER occurred in both control and Acsl1M2/2 mice
(Fig. 3B and Supplementary Fig. 3). However, although
fasting decreased the total RER during both the day and
night cycles, at every point during the dark cycle the RER
of the Acsl1M2/2 mice remained higher than that of the
controls, indicating increased systemic use of glucose by
Acsl1M2/2 mice, despite the fast (Fig. 3A and B). With
refeeding, the RER rose similarly in both genotypes, and
the amount of food eaten and heat produced were similar
(Fig. 3C and D). These data indicate that during fasting
when FA is normally the major fuel source, Acsl1M2/2
mice relied predominantly on nonlipid fuels; this require-
ment was less prominent in the nonfasted state, primarily
because exercise was minimal in both genotypes.
Acsl1M2/2 Mice Were Exercise Intolerant
During endurance exercise, Acsl1M2/2 mice ran only 46–
48% of the distance run by controls (1,522 6 122 vs.
3,175 6 327 m) (Fig. 4A and Supplementary Fig. 4A).
Blood lactate levels increased minimally (Fig. 4B), indi-
cating that the aerobic threshold had not been exceeded,
but both genotypes ceased to run when their blood glu-
cose concentrations dropped to ;40 mg/dL (Fig. 4C).
Although glucose concentrations declined more slowly
in control mice, at exhaustion, liver and muscle glycogen
levels were equally depleted in both genotypes, and both
were similarly hypoglycemic (Table 1). At exhaustion, plasma
creatine kinase levels were similar in both genotypes.
At the time point when Acsl1M2/2 mice refused to run
further, running control mice had blood glucose values of
87 6 7 mg/dL, despite depleted liver glycogen levels and
undetectable muscle glycogen levels (Table 1). Because the
basal content of liver and muscle glycogen was similar in
both genotypes (Fig. 2G) and since liver glycogen stores
were almost totally absent in the running controls, it
appeared that gluconeogenesis in control mice was
sufficient to avoid severe hypoglycemia, but Acsl1M2/2
mice, despite similar increases in the expression of hepatic
gluconeogenic genes (Fig. 4D), were unable to produce
enough glucose to compensate for the increased muscle
demand.
During prolonged exercise, hydrolyzed adipose FA
becomes a major fuel source for most tissues (31). Endur-
ance exercise increased plasma nonesterified FA levels in
both genotypes (Table 1). Although an increase in plasma
FA level normally increases liver TAG content during ex-
ercise, Acsl1M2/2 mice accumulated less hepatic TAG than
did controls, probably because more FA was used for en-
ergy in the liver (Table 1). Similarly, although plasma TAG
levels increased in both genotypes, there was less of an
increase in the Acsl1M2/2 mice (Table 1). Intramuscular
TAG is believed to be a major fuel source in muscle during
endurance exercise (32), and, at exhaustion, control mus-
cle had lost twice as much TAG (Table 1), which is con-
sistent with their ability to use lipid for energy.
Basal Muscle and Plasma Metabolites Differed in
Acsl1M2/2 and Control Mice
To understand how FA use differs in exercising muscle,
we profiled plasma and muscle metabolites. Consistent
with absent ACSL1 activity, resting Acsl1M2/2 muscle
contained lower levels of long-chain acyl-CoAs (Fig. 5A
and Supplementary Fig. 4A). Compared with controls,


















TAG (mg/dL) 38.0 6 3.6 34.9 6 2.9 75.6 6 5.3 73.1 6 4.4† 52.7 6 3.9*†
NEFA (mmol/L) 0.17 6 0.03 0.28 6 0.04* 1.28 6 0.02† 1.32 6 0.10†
b-Hydroxybutyrate (mmol/L) 0.33 6 0.03 0.35 6 0.05 0.99 6 0.20† 0.83 6 0.06†
Creatine kinase (units/L/min) 134 6 6 248 6 11‡ 2347 6 376† 2325 6 183†
Liver
Glycogen (mmol/g wet wt) 62.2 6 14.7 40.1 6 12.5 8.79 6 0.96 9.32 6 1.52† 7.77 6 0.52†
TAG (mg/mg wet wt) 15.7 6 1.5 15.6 6 2.1 36.9 6 3.0† 22.4 6 3.0*†
Muscle
Glycogen (mmol/g wet wt) 13.7 6 1.2 15.6 6 1.3 BD BD† BD†
TAG (mg/mg wet wt) 4.34 6 0.57 3.60 6 0.35 2.65 6 0.54† 2.70 6 0.44
Data are represented as the mean 6 SE. BD, below detectable concentration; NEFA, nonesterified FA; Resting, data before exercise and
after 2 h without food; Running control, data from control mice at the time when their Acsl1M2/2 littermates were exhausted. *P , 0.05,
Acsl1M2/2 compared with control littermates (same conditions). †P , 0.05, compared with resting state (same genotype). ‡P = 0.53.
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Figure 2—Acsl1M2/2 mice were more vulnerable to hypoglycemia and hepatic lipid accumulation after an overnight fast and required less
insulin to maintain euglycemia. Plasma glucose (A), nonesterified FAs (NEFAs) (B), TAG (C), and b-hydroxybutyrate (D) in female Acsl1M2/2
after food removal for 4 h (n = 9–11) or fasting overnight (O/N) (n = 7–17). E: Histology of representative liver slides from female control and
Acsl1M2/2 mice after an overnight fast (hematoxylin-eosin staining). Measurement after an overnight fast of liver TAG (F ) and glycogen (G)
content (n = 4–8). H: Gene expression of glucose-6-phosphatase (G6Pase), phosphoenolpyruvate (PEPCK), and hydroxymethylglutaryl-
CoA synthase-2 (HMGS2) in male mice (n = 6–10). I: Glycerol tolerance test in male mice after an overnight fast (n = 4). J: GLUT1 protein in
gastrocnemius muscle (n = 4–5). In control and Acsl1M2/2 female mice fed a high-fat diet (HFD) or matched standard diet (SD): glucose
tolerance (K); blood glucose and insulin levels before and 15 min after intraperitoneal administration of insulin (L); and insulin tolerance tests
and areas above the curve (AAC) after food removal for 4 h (M). N: pAkt (T308) and total Akt in female liver and gastrocnemius muscle 10
min after intraperitoneal PBS or insulin. C, control mice; K, knockout mice. #P < 0.05, vs. 4-h state (same genotype); *P < 0.05, vs. control
(same treatment).
28 Compartmentalized Acyl-CoA Metabolism Diabetes Volume 64, January 2015
acyl-CoA species of 14–18 carbons were 31–42% lower, but
little difference was observed for short-chain acyl-CoAs,
which are primarily products of amino acid degradation.
Basal levels of long-chain acyl-carnitine species were similar
in both genotypes (Fig. 5B). Acetyl-CoA is the final product of
pathways of FA oxidation, glycolysis, and amino acid degra-
dation. Basal acetyl-CoA levels were higher in Acsl1M2/2mus-
cle than in that of controls (Fig. 5A). Because FA oxidation
was severely impaired in Acsl1M2/2 muscle and basal tri-
carboxylic acid (TCA) cycle intermediates were not limiting
(Fig. 5C), this elevation in acetyl-CoA content, together with
the lower basal content of total amino acids in Acsl1M2/2
muscle, suggests an increase in the use of amino acids and
glucose for energy, even without exercise (Fig. 5D). Levels of
amino acids and acyl-carnitines in plasma did not differ
between genotypes (Supplementary Fig. 5B and C).
Muscle and Plasma Metabolites Differed After
Endurance Exercise
With endurance exercise, many acyl-CoA and acyl-carnitine
metabolites increased markedly. In muscle from exhausted
control mice, the levels of total acyl-CoA and long-chain
acyl-CoA species each rose threefold (Fig. 5A), which is con-
sistent with the normally enhanced influx of adipocyte-
derived FA and its metabolism to acyl-CoA. Surprisingly,
the increases of total acyl-CoA and long-chain acyl-CoA
were even greater in Acsl1M2/2 muscle than in that of
controls, with 4- and 10-fold increases, respectively. Total
long-chain acyl-CoA levels were 89% higher in exhausted
knockout muscle than in exhausted control muscle, despite
the absence of ACSL1, the 79% lower ACSL-specific activity,
and the absence of increases in mRNA expression of other
Acsl or Fatp isoforms (Fig. 6A) (33).
Acyl-carnitines, which normally correspond to acyl-
CoA levels, differed greatly by genotype. Endurance
exercise increased total and long-chain acyl-carnitines
5.5- and 23-fold, respectively, in control muscle, but
only 3- and 12-fold, respectively, in Acsl1M2/2 muscle.
Thus, in exhausted Acsl1M2/2 muscle, the levels of total
and individual long-chain acyl-carnitine species were 33–
77% lower than in exhausted controls, consistent with im-
paired FA oxidation (Fig. 5B), and levels of medium-chain
Figure 3—Acsl1M2/2 mice used more glucose as fuel source. A: Male mice (13 wk) were placed in metabolic chambers at 1:00 P.M. and
measurements were taken for 2 days before overnight (O/N; 5:00 P.M. to 10:00 A.M.) fasting. Mice were then refed with chow for 24 h (n = 4);
RER (VCO2/VO2) was monitored by indirect calorimetry during O/N fasting. Average RER (B), food intake (C ), and heat production (D) during
day and night cycles when the mice were fed, fasted, or refed. *P < 0.05, compared with control.
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acyl-carnitines were 30–77% lower than those in controls
(Supplementary Fig. 5). These data indicate that, despite
the marked decrease in skeletal muscle ACSL-specific activ-
ity in Acsl1M2/2 mice, during endurance exercise plasma
FAs taken up into muscle were converted to acyl-CoAs
by other ACSL isoforms; these acyl-CoAs, however,
remained in cytosolic pools that were inaccessible to carni-
tine palmitoyltransferase (CPT) 1 and b-oxidation enzymes
in mitochondria and peroxisomes (34).
Exercise increases the demand for carnitine as a carrier
for acyl groups (18). Although exercise diminished muscle
carnitine content in both genotypes (Fig. 5B), free carni-
tine levels remained higher in Acsl1M2/2 than in control
muscle, both in the resting state and at exhaustion, in-
dicating that the availability of carnitine had not limited
the conversion of acyl-CoAs to acyl-carnitines. Because
acyl-carnitines often reflect the flux of acyl-CoAs that
enter the b-oxidation pathway, the observation that mus-
cle from exhausted Acsl1M2/2 mice contained higher
amounts of long-chain acyl-CoAs but lower amounts of
long-chain acyl-carnitines (Fig. 5A and B) strongly sug-
gests that muscle contains separate pools of acyl-CoA.
Acsl3 mRNA was 40 and 30% higher, respectively, in rest-
ing and exhausted Acsl1M2/2 muscle, but none of the
other Acsl isoforms was specifically upregulated by exer-
cise (Fig. 6A). In control muscle, the total specific activity
derived from all ACSL isoforms was unchanged by exer-
cise; however, in muscle from exhausted Acsl1M2/2 mice,
ACSL-specific activity more than doubled (0.06 6 0.01 to
0.17 6 0.04 nmol/min/mg protein), suggesting that one
or more ACSL isoforms had been post-translationally ac-
tivated by exercise (Fig. 6B). Lack of change in intramus-
cular TAG content in Acsl1M2/2 mice (Table 1 and Fig. 6C)
suggests that the accumulating long-chain-CoAs were not
used for net TAG synthesis.
Intense exercise induces autophagy with the use of
proteolyzed amino acids for both fuel within muscle and
as a substrate for hepatic gluconeogenesis (35–37). With
exercise, control muscle content of proline, valine, leucine/
isoleucine, aspartate/asparagines, and tyrosine rose 57–
115% (Fig. 5D); plasma branch-chain and aromatic amino
acids increased two- to threefold (Supplementary Fig. 6B);
and amino acid degradation products (short-chain C3–C6
acyl-carnitines) rose 3.5-fold (Supplementary Fig. 5B).
In exhausted Acsl1M2/2 muscle, however, the levels of
proline, alanine, aspartate/asparagines, and the branched-
chain amino acids were low (Fig. 5D), probably because
these amino acids were diverted toward energy production
within muscle, as indicated by the marked rise in short-
chain acyl-CoA amino acid degradation products (Supple-
mentary Fig. 5A). TCA intermediates were not depleted
(Fig. 5C).
Figure 4—Muscle ACSL1 deficiency impaired endurance capacity. A: Total distance run during treadmill endurance exercise for Acsl1M2/2
mice (16 weeks of age, female). Blood lactate (B) and glucose (C) levels during endurance exercise. *P < 0.05, glucose from exhausted
Acsl1M2/2 mice compared with control mice that had run same distance (Run). D: mRNA expression of glucose-6-phosphatase (G6Pase),
phosphoenolpyruvate carboxykinase (PEPCK), FGF21, hydroxymethylglutaryl-CoA synthase-2 (HMGS2), and liver CPT1 (LCPT1) (n = 5–
13). *P < 0.05, compared with exhausted controls. Run, data from control mice collected at the time their Acsl1M2/2 littermates were
exhausted.
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DISCUSSION
Our data show that acyl-CoAs are poorly available for
b-oxidation in muscle if they have not been synthesized
by ACSL1 (Fig. 7). Endurance exercise in Acsl1M2/2 mice
caused a marked increase in muscle content of long-chain
acyl-CoAs. These acyl-CoAs, generated by other ACSL
isoforms, were not in a pool that was accessible to the
multiprotein CPT1-voltage-dependent anion channel-
ACSL1 complex (38,39), and could not be converted to
acyl-carnitines or enter the mitochondrial matrix. Thus,
acyl-CoAs are located in separate and distinct pools
within the cell. This is a surprising result, because am-
phipathic long-chain acyl-CoAs are water soluble and
can interact with membranes and with lipid binding
proteins that should allow them to move freely within
cells.
Because exercise-activated AMPK downregulates lipid
synthesis, lipid synthetic enzymes were apparently unable
to handle the excess FA that enters muscle during endur-
ance exercise. Exercise also enhances lipolysis (18,40). Con-
sistent with its critical importance in facilitating acyl-CoA
entry into mitochondria and in concert with other perox-
isome proliferator–activated receptor a targets, Acsl1
was the only Acsl mRNA upregulated by endurance exer-
cise in control mice (41,42). No change in expression of
other Acsl isoforms was observed in Acsl1M2/2 muscle,
but exercise increased the low basal specific activity of
ACSL in gastrocnemius muscle by 166%, suggesting possi-
ble post-transcriptional activation.
A second important finding was that the inability of
skeletal muscle to oxidize FA made Acsl1M2/2 mice vul-
nerable to systemic hypoglycemia. The dependence of
Figure 5—Metabolite changes in Acsl1M2/2 gastrocnemius muscle during endurance exercise (16–26 weeks of age, female). A: Muscle
free- and acyl-CoAs. B: Muscle free- and acyl-carnitines. C: Muscle Krebs cycle intermediates. D: Muscle amino acids (n = 5–9). #P< 0.05,
vs. 4-h state (same genotype); *P < 0.05, vs. control (same treatment). Running, data from control mice collected when their Acsl1M2/2
littermates were exhausted. a-KG, a-ketoglutarate; LC-AC, long-chain acyl-carnitine; LC-CoA, long-chain acyl-CoA; C, carbon number.
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Acsl1M2/2 muscle on glucose limited glucose availability for
other tissues, and gluconeogenesis was unable to supply
sufficient glucose during fasting or exercise. The metabolic
profile observed is consistent with muscle that is unable to
oxidize FA and, instead, uses hydrolyzed amino acids for
energy rather than releasing them as substrates for hepatic
gluconeogenesis. Thus, Acsl1M2/2 muscle burned more glu-
cose during exercise, and its demand for nonlipid fuel im-
paired systemic energy homeostasis. The increased demand
for glucose during an overnight fast was accompanied by
increased muscle GLUT1 protein and enhanced insulin sen-
sitivity in both the liver and muscle.
The marked decrease in FA b-oxidation in Acsl1M2/2
muscle resulted in a fasting phenotype of hypoglycemia,
elevated plasma FA levels, and fatty liver similar to that of
humans and animals with genetic defects in FA oxidation
(43,44). However, Acsl1M2/2 mice differed from other
models of defective FA oxidation in that muscle TAG
did not accumulate. Further, because the liver retained
normal ACSL activity, fasting-induced hypoketonemic
hypoglycemia did not occur (43).
Metabolic limitations on endurance exercise have been
variously attributed to low intramuscular fuel stores (45),
diminished liver glycogen stores (41), lack of glucose or
ketone production by the liver (43), or an impaired ability
of muscle to take up and oxidize available fuels, including
glucose (46) and FA (43). Diminished endurance in rats is
associated with hypoglycemia (45) and with low glycogen
content in discrete cerebral regions (47), which may con-
tribute to exhaustion (48).
Figure 6—Muscle ACSL1 regulates fuel use and whole-body metabolism. A: mRNA expression of Acsl isoforms in gastrocnemius muscle
relative to tubulin (female, n = 7–9). B: ACSL-specific activity within gastrocnemius homogenates (n = 4). C: Intramuscular TAG in
gastrocnemius muscle after endurance exercise (n = 6–8). #P < 0.05, vs. 4-h state (same genotype); *P < 0.05, vs. control (same
treatment). Exh, exhausted; Rest, resting.
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Figure 7—Skeletal muscle metabolism in control and Acsl1M2/2 mice. Exercising control muscle. Initial fuels include glucose hydrolyzed from
hepatic and muscle glycogen and intramuscular TAG. Activation of AMPK suppresses TAG synthesis and accelerates mitochondrial FA
oxidation, and autophagy releases amino acids, which are exported to provide a substrate for hepatic gluconeogenesis (37). As exercise
continues, Acsl1 mRNA increases, and epinephrine increases the supply of adipocyte-derived long-chain (LC)-FA, which are activated by
ACSL1 and converted to LC-acyl-carnitines (ACs) by CPT1 and, within the mitochondria, back to LC-CoA by CPT2. Mitochondrial oxidation
produces shorter-chain acyl-CoAs and their AC counterparts. Some amino acids that arise from protein hydrolysis contribute to TCA cycle
intermediates and to acetyl-CoA for energy production. Hepatic glucose, now derived via amino acid–fueled gluconeogenesis, continues to
enter the glycolytic pathway, but the use of LC-FA spares muscle demand for glucose. In addition to ACs of different chain lengths that move
out of the mitochondria into the cytosol, ACs derived from hepatic FA oxidation are released into the blood and equilibrate across the muscle
plasma membrane. Exercising Acsl1M2/2 muscle. When ACSL1 is absent, other ACSL isoforms (ACSL?) activate the large amount of entering
LC-FA. Most, but perhaps not all, of the LC-CoA produced by these ACSL? lack ready access to CPT1 and cannot be converted to LC-AC
and enter the mitochondria. (For simplicity, we have not shown a theoretical pathway by which some FAs might be activated by ACSL? and
oxidized in the absence of ACSL1 [see Fig. 1D]; these pathways 1) might provide some LC-CoA at the mitochondrial surface with access to
CPT1 or 2) might provide medium-chain (MC)-CoA in Acsl1M2/2 muscle [Supplementary Fig. 4A], which can enter the mitochondria without
CPT1.) The cell content of LC-CoAs increases because of their diminished entry into both oxidative and synthetic pathways. Failure to switch
to the use of LC-FA for oxidation enhances glucose entry and oxidation and increases the use of muscle protein–derived amino acid that is
converted to acetyl-CoA and TCA cycle intermediates. Fewer amino acids are released by muscle to supply the substrate for hepatic
gluconeogenesis. As a consequence, systemic hypoglycemia ensues and the capacity for endurance exercise is impaired.
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Failure of muscle to switch to FA use rendered Acsl1M2/2
mice unable to run optimally, despite normal hepatic FA
oxidation and comparable upregulation of mRNA for he-
patic gluconeogenic genes. Although a mild myopathy was
present, the most striking difference between the running
genotypes was the concentration of plasma glucose.
Acsl1M2/2 mice refused to run when their glucose concen-
trations dropped to ;40 mg/dL, while the controls, with
glucose concentrations of ;90 mg/dL, continued to run,
despite levels of liver and muscle glycogen, muscle TAG,
and plasma ketones, FA, and amino acids equivalent to
those of the knockouts. Thus, hypoglycemia, causing central
fatigue and an inadequate peripheral energy supply, was the
deciding feature in the refusal of both genotypes to run.
In summary, ACSL1 is essential for FA oxidation in
skeletal muscle, and acyl-CoA synthesis by other ACSL
isoforms cannot compensate (Fig. 7). ACSL1 is located on
both the endoplasmic reticulum and the mitochondrial
outer membrane in rat liver (38,49) and 3T3-L1 adipo-
cytes (50), but the subcellular location of ACSL1 in muscle
has not been investigated. The absence of ACSL1 resulted
in an inappropriate dependence on glucose for muscle
energy, such that systemic glucose homeostasis became
severely compromised. In human and animal models
with defective FA oxidation, the hypoglycemia that occurs
with fasting or exercise has been attributed to a lack of
hepatic FA metabolism and diminished ATP production to
power gluconeogenesis. In Acsl1M2/2 mice, however, hy-
poglycemia occurred despite the fact that hepatic FA ox-
idation was not impaired. Instead, the muscle-specific
defect in FA oxidation drained the glucose supply, and
the likely increased use of amino acids within muscle pre-
cluded amino acid availability as a substrate for hepatic
gluconeogenesis. Thus, during both fasting and endurance
exercise, the liver was unable to synthesize sufficient glu-
cose to prevent hypoglycemia, a dramatic example of the
interdependence of muscle and liver fuel metabolism.
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